NEAT TAVI: Neurocognitive Assessment in TAVI

Sponsor
Brighton and Sussex University Hospitals NHS Trust (Other)
Overall Status
Completed
CT.gov ID
NCT06120946
Collaborator
University of Melbourne (Other), Terumo Medical Corporation (Industry)
120
1
18.9
6.4

Study Details

Study Description

Brief Summary

Severe aortic stenosis is a common heart condition affecting elderly patients. Degeneration of the aortic valve (oneway valve between the heart and the aorta) causes high resistence to blood flow, resulting in strain on the heart and the potential for heart failure and death. Treatment of aortic stenosis has traditionally been with open heart surgery. A new procedure called transcatheter aortic valve implantation (TAVI) allows new aortic valves to be implanted through the femoral arteries, resulting in equivalent outcomes to open surgery with a more rapid recovery. Some complications remain present however, including the risk of debris released during the valve implantation being carried by the blood stream into the brain. This may lead to strokes and a loss of mental capacity. Devices that filter the blood stream and capture this debris have now been developed but are of uncertain benefit. We plan to investigate the brain function of patients who have been randomly assigned to the TAVI procedure with and without the use of filters to see if there are any cognitive benefits to the use of this technology.

Patients who are enrolled in the BHF PROTECT-TAVI trial will be invited to partcipate in this trial. They will have already been randomly assigned to TAVI with or without cerebral filter use. We will perform a series of bedside clinical tests (lasting ~40 minutes) involving questionnaires, pen & paper and computer-based tasks. These will be performed both pre- and post-TAVI. There is no change to routine patient care. Data will be analysed with the assistance of trained neuropsychologists and will provide a valuable insight into the performance and role of the cerebral filter for TAVI patients in the future.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    120 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Influence of Cerebral Protection on Neurocognitive Outcomes Following Transcatheter Aortic Valve Implantation (TAVI)
    Actual Study Start Date :
    May 18, 2021
    Actual Primary Completion Date :
    Jun 13, 2022
    Actual Study Completion Date :
    Dec 13, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Control arm

    Patients randomised in the BHF PROTECT study to TAVI without Sentinel cerebral embolic protection

    Intervention arm

    Patients randomised in the BHF PROTECT study to TAVI with Sentinel cerebral embolic protection

    Outcome Measures

    Primary Outcome Measures

    1. Neurocognitive change [<3 days post-TAVI]

      Neurocognitive change by individual scores for each task performed

    Secondary Outcome Measures

    1. Neurocognitive change [12-months post-TAVI]

      Neurocognitive change by individual scores for each task performed

    Other Outcome Measures

    1. Subgroup interactions [<3 days post-TAVI]

      Age, baseline cognitive score, prior CVA, type of TAVI device, procedural pre- and post-dilation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Randomised in the BHF PROTECT-TAVI trial (assessing stroke outcomes in TAVI with and without filter use).

    • Willing to provide informed consent for participation in this trial.

    Exclusion Criteria:
    • Participant has been excluded from use of the filter device due to anatomical or clinical contra-indications.

    • Inadequate English skills.

    • Inability to complete assessment tasks due to visual or auditory impairment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Royal Sussex County Hospital Brighton East Sussex United Kingdom BN2 5BE

    Sponsors and Collaborators

    • Brighton and Sussex University Hospitals NHS Trust
    • University of Melbourne
    • Terumo Medical Corporation

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Brighton and Sussex University Hospitals NHS Trust
    ClinicalTrials.gov Identifier:
    NCT06120946
    Other Study ID Numbers:
    • NEAT TAVI
    First Posted:
    Nov 7, 2023
    Last Update Posted:
    Nov 7, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 7, 2023